Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma

Cancer Genetics

Volumn 205, Issue 9, 2012, Pages 474-478

  Hucthagowder, Vishwanathan ^a   Meyer, Rekha ^a   Mullins, Chelsea ^a   Nagarajan, Rakesh ^a,b   DiPersio, John F ^a,b   Vij, Ravi ^a,b   Tomasson, Michael H ^a,b   Kulkarni, Shashikant ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Cancer; Multiple myeloma; Mutation analysis; RAS; Resequencing; Tyrosine kinase

Indexed keywords

INSULIN RECEPTOR; K RAS PROTEIN; PROTEIN LTK; PROTEIN MERTK; PROTEIN PIK3CA; PROTEIN TYROSINE KINASE; RAS PROTEIN; REGULATOR PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INSR GENE; LTK GENE; MERTK GENE; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE; ONCOGENE K RAS; ONCOGENE RAS; PIK3CA GENE; PRIORITY JOURNAL; REPEAT PROCEDURE; SEQUENCE ANALYSIS; TYROSINE KINASE GENE;

BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; GENES, RAS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; PROTEIN-TYROSINE KINASES; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

EID: 84869822590     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.06.007     Document Type: Article

References (21)

1. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
2. Claudio J.O., Zhan F., Zhuang L., et al. Expression and mutation status of candidate kinases in multiple myeloma. Leukemia 2007, 21:1124-1127.
3. Bezieau S., Devilder M.C., Avet-Loiseau H., et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001, 18:212-224.
4. Onwuazor O.N., Wen X.Y., Wang D.Y., et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003, 102:772-773.
5. Liu P., Leong T., Quam L., et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996, 88:2699-2706.
6. Kalakonda N., Rothwell D.G., Scarffe J.H., et al. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001, 98:1555-1560.
7. Intini D., Agnelli L., Ciceri G., et al. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma. Hematol Oncol 2007, 25:6-10.
8. Martin P., Santon A., Garcia-Cosio M., et al. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies. Int J Oncol 2005, 27:1023-1028.
9. Chng W.J., Gonzalez-Paz N., Price-Troska T., et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008, 22:2280-2284.
10. Stephens P., Edkins S., Davies H., et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005, 37:590-592.
11. Greenman C., Stephens P., Smith R., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
12. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
13. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
14. Ley T.J., Minx P.J., Walter M.J., et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci U S A 2003, 100:14275-14280.
15. Tomasson M.H., Xiang Z., Walgren R., et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008, 111:4797-4808.
16. Chen K., McLellan M.D., Ding L., et al. PolyScan: an automatic indel and SNP detection approach to the analysis of human resequencing data. Genome Res 2007, 17:659-666.
17. Quinlan M.P., Settleman J. Isoform-specific ras functions in development and cancer. Future Oncol 2009, 5:105-116.
18. Karakas B., Bachman K.E., Park B.H. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006, 94:455-459.
19. Ismail S.I., Mahmoud I.S., Msallam M.M., Sughayer M.A. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. Leuk Res 2010, 34:824-826.
20. Futreal P.A., Coin L., Marshall M., et al. A census of human cancer genes. Nat Rev Cancer 2004, 4:177-183.
21. Sprynski A.C., Hose D., Kassambara A., et al. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia 2010, 24:1940-1950.